EFFECTIVENESS OF RIFAMPIN, RIFABUTIN, AND RIFAPENTINE FOR PREVENTIVE THERAPY OF TUBERCULOSIS IN MICE

被引:109
作者
JI, BH
TRUFFOTPERNOT, C
LACROIX, C
RAVIGLIONE, MC
OBRIEN, RJ
OLLIARO, P
ROSCIGNO, G
GROSSET, J
机构
[1] UNIV PARIS 06,F-75634 PARIS 13,FRANCE
[2] CTR HOSP GEN,LE HAVRE,FRANCE
[3] WHO,CH-1211 GENEVA,SWITZERLAND
[4] FARMITALIA CARLO ERBA SPA,MILAN,ITALY
[5] MERRELL DOW RES INST,RES CTR,EGHAM,BERKS,ENGLAND
来源
AMERICAN REVIEW OF RESPIRATORY DISEASE | 1993年 / 148卷 / 06期
关键词
D O I
10.1164/ajrccm/148.6_Pt_1.1541
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
To identify alternative regimens for preventive therapy of tuberculosis, the pharmacokinetics and antimicrobial activities of rifampin (RMP), rifabutin (RBT), and rifapentine (RPT) were compared in BCG-vaccinated and M. tuberculosis-infected immunocompetent mice. RPT showed the highest serum peak level (Cmax) and the longest half-life (t(1/2)), whereas RBT displayed the lowest Cmax and the shortest t(1/2). On weight-to-weight basis, both RPT and RBT were more bactericidal than RMP. The activity of RMP was significantly reduced when the frequency of administration was reduced from six to three times weekly, whereas significant bactericidal activity was still observed in mice treated with RPT, 10 mg/kg up to once fortnightly, or RBT, 10 mg/kg twice weekly. Because the bactericidal activity of RBT, 10 mg/kg six times/wk for 6 wk, or RPT, 10 mg/kg two times/wk for 12 wk, was comparable to that of RMP, 10 mg/kg six times/wk for 12 wk in mice, the two regimens are appropriate for clinical trials of preventive therapy of tuberculosis.
引用
收藏
页码:1541 / 1546
页数:6
相关论文
共 34 条
[1]   TUBERCULOSIS IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
BARNES, PF ;
BLOCH, AB ;
DAVIDSON, PT ;
SNIDER, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (23) :1644-1650
[2]   THE EARLY BACTERICIDAL ACTIVITY OF RIFABUTIN MEASURED BY SPUTUM VIABLE COUNTS IN HONG-KONG PATIENTS WITH PULMONARY TUBERCULOSIS [J].
CHAN, SL ;
YEW, WW ;
MA, WK ;
GIRLING, DJ ;
ABER, VR ;
FELMINGHAM, D ;
ALLEN, BW ;
MITCHISON, DA .
TUBERCLE AND LUNG DISEASE, 1992, 73 (01) :33-38
[3]  
COMSTOCK GW, 1984, MYCOBACTERIA SOURCEB, P1071
[4]  
DELLABRUNA C, 1983, J ANTIBIOT, V36, P1502
[5]   ACTIVITY INVITRO OF RIFABUTIN, FCE-22807, RIFAPENTINE, AND RIFAMPIN AGAINST MYCOBACTERIUM-MICROTI AND MYCOBACTERIUM-TUBERCULOSIS AND THEIR PENETRATION INTO MOUSE PERITONEAL-MACROPHAGES [J].
DHILLON, J ;
MITCHISON, DA .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1992, 145 (01) :212-214
[6]   ACTIVITY OF 2 LONG-ACTING RIFAMYCINS, RIFAPENTINE AND FCE-22807, IN EXPERIMENTAL MURINE TUBERCULOSIS [J].
DHILLON, J ;
DICKINSON, JM ;
GUY, JA ;
NG, TK ;
MITCHISON, DA .
TUBERCLE AND LUNG DISEASE, 1992, 73 (02) :116-123
[7]   INVITRO ACTIVITY OF NEW RIFAMYCINS AGAINST RIFAMPICIN-RESISTANT MYCOBACTERIUM-TUBERCULOSIS AND MAIS-COMPLEX MYCOBACTERIA [J].
DICKINSON, JM ;
MITCHISON, DA .
TUBERCLE, 1987, 68 (03) :177-182
[8]   INVITRO PROPERTIES OF RIFAPENTINE (MDL473) RELEVANT TO ITS USE IN INTERMITTENT CHEMOTHERAPY OF TUBERCULOSIS [J].
DICKINSON, JM ;
MITCHISON, DA .
TUBERCLE, 1987, 68 (02) :113-118
[9]  
FARER LS, 1982, AM REV RESPIR DIS, V125, P102
[10]  
Ferebee SH, 1969, ADV TUBERC RES, V17, P28